#United States #Las Vegas #Sarcopenia #MYMD-1 #Sarconeos

Sarcopenia Market Forecast Report (2020-2034)

The sarcopenia market, responsible for addressing a significant age-related muscle loss condition, is anticipated to undergo substantial growth in the upcoming years. According to a report by DelveInsight, the market is projected to reach an impressive USD 2.2 billion by 2024, with an expected compound annual growth rate (CAGR) of 8.1% through 2034. This growth is largely attributed to the increasing prevalence of sarcopenia and the introduction of innovative treatment options that target various patient demographics, including those suffering from liver cirrhosis, obesity, and chronic inflammatory conditions.

Understanding Sarcopenia

Sarcopenia is a muscle condition that is particularly prevalent in older adults, affecting approximately 15% of this population. It is characterized by the progressive loss of skeletal muscle mass and functionality, which can lead to serious health outcomes such as increased frailty and a higher risk of falls. In 2024, the total diagnosed cases of sarcopenia in the major markets (referred to as 7MM, consisting of the United States, EU4 - Germany, France, Italy, Spain - and the United Kingdom, as well as Japan) were calculated at 19.8 million—a figure that is expected to rise significantly over the next decade.

Current Treatment Landscape

Currently, there are no FDA-approved medications for sarcopenia. Treatment recommendations often include resistance exercise and nutritional adjustments, particularly ensuring adequate intake of protein and vitamin D, alongside lifestyle changes aimed at enhancing physical activity. While these methods are critical for managing the condition, they highlight a notable gap in pharmacological interventions.
Several therapies are in various stages of development, aiming to fill this void. These include:

• - MYMD-1 (developed by TNF Pharmaceuticals), which is an orally administered TNF-α inhibitor showing promise in early trials.
• - Sarconeos (formerly known as BIO101) from Biophytis, a small molecule targeting neuromuscular disorders and aimed at promoting resilience in muscle function.
• - LPCN 1148, an oral prodrug of testosterone by Lipocine, currently being evaluated for its effects on sarcopenia associated with liver cirrhosis.

Pipeline Innovations

The pipeline for sarcopenia therapeutics is gaining momentum, with a variety of innovative treatments entering clinical trials. Notable candidates include:

• - Froniglutide, a GLP-1 receptor agonist being studied by ImmunoForge.
• - KER-065, a product from Keros Therapeutics targeting ActRIIB-Fc
• - BPM 31510, focusing on the aerobic glycolytic pathway, developed by BPGbio.

Each of these therapies tackles sarcopenia from unique angles, aiming to enhance muscle mass and strength, thereby improving patients' quality of life.

Market Dynamics

The overall dynamics of the sarcopenia market are being reshaped by a combination of an aging global population and ongoing research initiatives aimed at better understanding the underlying mechanisms of the condition. As awareness regarding sarcopenia grows, along with the demand for effective treatments, this sector is poised for robust investment and development. Key players such as TNF Pharmaceuticals, Biophytis, and Lipocine are at the forefront of this shift, advancing their respective therapies towards market readiness

Conclusion

In conclusion, the sarcopenia market represents a critical area for development in geriatric health. The anticipated growth is supported by emerging therapeutic options, addressing an urgent need for approved treatments. This evolving landscape signifies not only a potential shift in patient care but also an exciting avenue for pharmaceutical innovation, ultimately aiming for improved health outcomes for millions suffering from this prevalent condition.

For further insights and updates in the sarcopenia treatment arena, interested parties can explore ongoing clinical trials and the developmental pipeline through platforms such as Sarcopenia Clinical Trials and DelveInsight's comprehensive health reports.